TRV GP III, LLC - Q3 2022 holdings

$229 Million is the total value of TRV GP III, LLC's 6 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 14.3% .

 Value Shares↓ Weighting
PLRX SellPLIANT THERAPEUTICS, INC.$80,200,000
+71.5%
3,839,160
-34.3%
35.02%
+83.1%
RVMD SellREVOLUTION MEDICINES, INC.$71,073,000
-28.6%
3,604,130
-29.4%
31.03%
-23.7%
VYGR SellVOYAGER THERAPEUTICS, INC.$32,139,000
-14.9%
5,428,933
-15.1%
14.03%
-9.2%
FULC  FULCRUM THERAPEUTICS, INC.$32,054,000
+65.1%
3,962,2020.0%14.00%
+76.2%
DBTX  DECIBEL THERAPEUTICS, INC.$10,863,000
-17.8%
3,139,6850.0%4.74%
-12.3%
JNCE  JOUNCE THERAPEUTICS, INC.$2,688,000
-22.8%
1,148,7800.0%1.17%
-17.6%
NRIX ExitNURIX THERAPEUTICS, INC.$0-1,922,549
-100.0%
-9.96%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Mark Levin #1
  • Kevin P. Starr #2
  • Robert I. Tepper #3
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-11-03
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
VOYAGER THERAPEUTICS, INC.22Q1 202374.0%
JOUNCE THERAPEUTICS, INC.20Q3 202224.5%
PLIANT THERAPEUTICS, INC.14Q3 2023100.0%
FULCRUM THERAPEUTICS, INC.14Q4 202243.8%
REVOLUTION MEDICINES, INC.12Q4 202253.8%
DECIBEL THERAPEUTICS, INC.10Q2 202366.3%
NEON THERAPEUTICS, INC.8Q1 202041.1%
NURIX THERAPEUTICS, INC.8Q2 202217.7%
RELAY THERAPEUTICS, INC.2Q4 202037.7%
MYOKARDIA, INC.2Q1 201822.1%

View TRV GP III, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-13
13F-HR2023-08-10
13F-HR2023-05-12
13F-HR2023-02-14
42023-02-06
42023-02-01
42023-01-31
42023-01-26
42023-01-24

View TRV GP III, LLC's complete filings history.

Compare quarters

Export TRV GP III, LLC's holdings